Franklin Parlapiano Turner & Welch LLC Takes $7.49 Million Position in Stryker Corporation $SYK

Key Points

• Franklin Parlapiano Turner & Welch LLC acquired 23,776 Stryker shares worth approximately $7.49 million, making the medical technology company its 19th-largest holding and representing about 1.7% of its portfolio.
• Stryker reported quarterly earnings of $3.69 per share, beating estimates by $0.20, while revenue rose 9.4% year over year to $6.59 billion. The company maintained fiscal 2026 EPS guidance of $14.95 to $15.10.
• The company declared a quarterly dividend of $0.88 per share, equating to a 1.0% annualized yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $386.28, despite recent insider selling and some target reductions.

Franklin Parlapiano Turner & Welch LLC acquired a new position in Stryker Corporation (NYSE:SYK - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 23,776 shares of the medical technology company's stock, valued at approximately $7,486,000. Stryker makes up about 1.7% of Franklin Parlapiano Turner & Welch LLC's holdings, making the stock its 19th largest holding.

A number of other large investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in Stryker by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company's stock worth $11,917,396,000 after acquiring an additional 133,892 shares during the last quarter. State Street Corp grew its position in shares of Stryker by 2.1% in the fourth quarter. State Street Corp now owns 15,254,407 shares of the medical technology company's stock valued at $5,374,731,000 after purchasing an additional 311,507 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Stryker by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company's stock worth $2,636,238,000 after purchasing an additional 69,851 shares during the last quarter. Wellington Management Group LLP lifted its stake in Stryker by 22.6% in the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company's stock valued at $2,282,192,000 after buying an additional 1,198,665 shares in the last quarter. Finally, Norges Bank acquired a new stake in Stryker during the 4th quarter valued at $1,822,272,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Price Performance

Shares of Stryker stock opened at $338.85 on Monday. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $396.86. The stock has a market capitalization of $129.97 billion, a P/E ratio of 35.11, a PEG ratio of 2.16 and a beta of 0.76. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The business's fifty day moving average price is $320.11 and its 200 day moving average price is $333.92.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm's revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the firm posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, research analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker's dividend payout ratio (DPR) is currently 36.48%.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the firm's stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 4.60% of the company's stock.

Analysts Set New Price Targets

SYK has been the subject of a number of analyst reports. Canaccord Genuity Group cut their price target on Stryker from $435.00 to $400.00 and set a "buy" rating for the company in a report on Friday, May 1st. Citigroup restated an "outperform" rating on shares of Stryker in a report on Monday, August 3rd. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on shares of Stryker in a research report on Friday, May 1st. Evercore set a $350.00 price target on Stryker in a research note on Monday, July 6th. Finally, JPMorgan Chase & Co. decreased their price objective on Stryker from $400.00 to $350.00 and set an "overweight" rating on the stock in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Stryker has an average rating of "Moderate Buy" and a consensus price target of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source